BioSpace News Archive

InDex Pharmaceuticals Holding AB today announced the publication of a post-hoc analysis of COLLECT study data.

MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC)

GRAIL, Inc. today announced that new data from the Circulating Cell-free Genome Atlas (CCGA) study will be presented by Minetta Liu, MD, Research Chair and Professor, Department of Oncology, Mayo Clinic, in an oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19 – 23 in Munich, Germany.

BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer

VIB4920 demonstrated proof-of-concept in a Phase 1b multiple-ascending dose study

Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response

Findings with combination therapy of anti-PD-1 and CXCR4 antagonist in patients with clear cell renal cell carcinoma (ccRCC) presented in Poster Discussion session at ESMO 2018

Orthofix Medical Inc. today announced that it plans to release financial results for the third quarter 2018 after market close on Monday, October 29, 2018.

Integrated Cannabis Company, Inc. is pleased to announce the signing of a Letter of Intent (the “LOI”) to acquire all of the issued and outstanding securities of Critical Mass Industries, LLC (“CMI”), a Colorado-based cannabis leader operating successfully for nearly 10-years under the brands Good Meds ( http://www.GoodMeds.com ) and BOSM Labs (http://www.BosmLabs.com ) (the “Proposed Transaction”).

Amneal Pharmaceuticals, Inc. today announced that it has received FDA approval for a generic version of IsuprelTM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The Company has immediately initiated commercialization activities.